Vaccination of patients with allergic disease against novel coronavirus infection: position paper of the Russian Association of Allergology and Clinical Immunology
- Authors: Ilyina N.I.1,2, Kurbacheva O.M.1,2, Latysheva E.A.3,4, Latysheva T.V.1,2, Nazarova E.V.1, Nenasheva N.M.5, Fedenko E.S.1, Khaitov M.R.1,4, Shartanova N.V.1
-
Affiliations:
- National Research Center — Institute of Immunology Federal Medical-Biological Agency of Russia
- Moscow State University of Medicine and Dentistry named after A.I. Evdokimov
- National Research Center – Institute of Immunology Federal Medical-Biological Agency of Russia
- Pirogov Russian National Research Medical University
- Russian Medical Academy of Continuous Professional Education
- Issue: Vol 18, No 3 (2021)
- Pages: 93-97
- Section: Clinical practice guidelines
- URL: https://journals.rcsi.science/raj/article/view/121680
- DOI: https://doi.org/10.36691/RJA1479
- ID: 121680
Cite item
Full Text
Abstract
One of the key tasks of the previous year is to stop the spread of coronavirus disease (COVID-19), which became a pandemic that led to the deaths of more than 4 million people worldwide and more than 140 thousand deaths in Russia. COVID-19 is caused by the severe acute respiratory syndrome coronavirus 2 (2019-nCoV) virus of the coronavirus family. Vaccination plays a leading role in ending the pandemic. Currently, five vaccines against COVID-19 have been registered in Russia, namely, Sputnik V, Sputnik light, EpiVacCorona, EpiVacCorona-Н, and СoviVak. The short follow-up period and absence of randomized placebo-controlled trials of COVID-19 vaccines in certain patients with chronic diseases lead to several questions about the effectiveness/safety of vaccination in these patients. Given the wide spread of allergic diseases and the heterogeneity of patients with allergopathology, experts of the Russian Association of Allergology and Clinical Immunology have developed and approved a position paper on vaccination of patients with allergopathology.
Full Text
##article.viewOnOriginalSite##About the authors
Natalya I. Ilyina
National Research Center — Institute of Immunology Federal Medical-Biological Agency of Russia; Moscow State University of Medicine and Dentistry named after A.I. Evdokimov
Email: instimmun@yandex.ru
ORCID iD: 0000-0002-3556-969X
SPIN-code: 6715-5650
MD, Dr. Sci. (Med.), Professor
Russian Federation, 24 Kashirskoe shosse, Moscow, 115522; MoscowOksana M. Kurbacheva
National Research Center — Institute of Immunology Federal Medical-Biological Agency of Russia; Moscow State University of Medicine and Dentistry named after A.I. Evdokimov
Email: kurbacheva@gmail.com
ORCID iD: 0000-0003-3250-0694
SPIN-code: 5698-6436
MD, Dr. Sci. (Med.), Professor
Russian Federation, 24 Kashirskoe shosse, Moscow, 115522; MoscowElena A. Latysheva
National Research Center – Institute of Immunology Federal Medical-Biological Agency of Russia; Pirogov Russian National Research Medical University
Author for correspondence.
Email: ealat@mail.ru
ORCID iD: 0000-0002-1606-205X
SPIN-code: 2063-7973
MD, Dr. Sci. (Med.)
Russian Federation, 24, Kashirskoye shosse, Moscow, 115522; MoscowTatiana V. Latysheva
National Research Center — Institute of Immunology Federal Medical-Biological Agency of Russia; Moscow State University of Medicine and Dentistry named after A.I. Evdokimov
Email: tvlat@mail.ru
ORCID iD: 0000-0003-1508-0640
SPIN-code: 8929-7644
MD, Dr. Sci. (Med.), Professor
Russian Federation, 24 Kashirskoe shosse, Moscow, 115522; MoscowEvgeniya V. Nazarova
National Research Center — Institute of Immunology Federal Medical-Biological Agency of Russia
Email: ev.nazarova@nrcii.ru
ORCID iD: 0000-0003-0380-6205
SPIN-code: 4788-7407
MD, Cand. Sci. (Med.)
Russian Federation, 24 Kashirskoe shosse, Moscow, 115522Natalia M. Nenasheva
Russian Medical Academy of Continuous Professional Education
Email: 1444031@gmail.com
ORCID iD: 0000-0002-3162-2510
SPIN-code: 3363-6170
MD, Dr. Sci. (Med.), Professor
Russian Federation, MoscowElena S. Fedenko
National Research Center — Institute of Immunology Federal Medical-Biological Agency of Russia
Email: efedks@gmail.com
ORCID iD: 0000-0003-3358-5087
SPIN-code: 5012-7242
MD, Dr. Sci. (Med.), Professor
Russian Federation, 24 Kashirskoe shosse, Moscow, 115522Musa R. Khaitov
National Research Center — Institute of Immunology Federal Medical-Biological Agency of Russia; Pirogov Russian National Research Medical University
Email: mr.khaitov@nrcii.ru
ORCID iD: 0000-0003-4961-9640
SPIN-code: 3199-9803
MD, Dr. Sci. (Med.), Professor, Corresponding Member of the Russian Academy of Sciences
Russian Federation, 24 Kashirskoe shosse, Moscow, 115522; MoscowNatalia V. Shartanova
National Research Center — Institute of Immunology Federal Medical-Biological Agency of Russia
Email: nshartanova@yandex.ru
ORCID iD: 0000-0002-1197-9002
SPIN-code: 6483-8901
MD, Dr. Sci. (Med.)
Russian Federation, 24 Kashirskoe shosse, Moscow, 115522References
- World Health Organization. Coronavirus disease (COVID-19) pandemic. (In Russ). Available from: https://www.who.int/. Accessed: Aug 15, 2021.
- American Academy of Allergy, Asthma & Immunology. Allergen immunotherapy and COVID-19/SARS-CoV-2 vaccination. (In Russ). Available from: https://www.aaaai.org/Allergist-Resources/Ask-the-Expert/Answers/Old-Ask-the-Experts/allergenimm. Accessed: Aug 15, 2021.
- American Academy of Allergy, Asthma & Immunology. COVID vaccine reaction in a patient with asthma. (In Russ). Available from: https://www.aaaai.org/Allergist-Resources/Ask-the-Expert/Answers/Old-Ask-the-Experts/covidvreac. Accessed: Aug 15, 2021.
- Global Initiative for Asthma. GINA guidance about COVID-19 and asthma, updated 30 March 2021. GINA Global Strategy for Asthma Management and Prevention. (In Russ). Available from: https://ginasthma.org/wp-content/uploads/2021/03/21_03_30-GINA-COVID-19-and-asthma.pdf. Accessed: Aug 15, 2021.
- Bohlke K, Davis RL, Marcy SM, et al. Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics. 2003;112(4):815–820. doi: 10.1542/peds.112.4.815
- Jutel M, Torres MJ, Palomares O, et al. COVID-19-vaccination in patients receiving allergen immunotherapy (AIT) or biologics ― EAACI recommendations. Authorea. June 24, 2021. doi: 10.22541/au.162452341.15060228/v1
- Klimek L, Bergmann KC, Brehler R, et al. Praktischer Umgang mit allergischen Reaktionen auf COVID-19-Impfstoffe: Ein Positionspapier des Ärzteverbands Deutscher Allergologen (AeDA), der Deutschen Gesellschaft für Allergologie und klinische Immunologie (DGAKI), der Gesellschaft für Pädiatrische Allergologie und Umweltmedizin (GPA) und der Österreichischen Gesellschaft für Allergologie und Immunologie (ÖGAI). [In German] Allergo J. 2021;30(3):22–43. doi: 10.1007/s15007-021-4773-1.
- The procedure for vaccination of the adult population against COVID-19. Temporary methodological recommendations. Moscow; 2021.
Supplementary files
